Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19.
METHODS: An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission.
RESULTS: The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model.
CONCLUSION: Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.
| Errataetall: |
CommentIn: Ann Rheum Dis. 2023 Jan;82(1):e2. - PMID 33127661 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 79(2020), 11 vom: 07. Nov., Seite 1393-1399 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Freites Nuñez, Dalifer D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.10.2020 Date Revised 29.08.2023 published: Print-Electronic CommentIn: Ann Rheum Dis. 2023 Jan;82(1):e2. - PMID 33127661 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2020-217984 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313441804 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313441804 | ||
| 003 | DE-627 | ||
| 005 | 20231225150559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2020-217984 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313441804 | ||
| 035 | |a (NLM)32769150 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Freites Nuñez, Dalifer D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.10.2020 | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Rheum Dis. 2023 Jan;82(1):e2. - PMID 33127661 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19 | ||
| 520 | |a METHODS: An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission | ||
| 520 | |a RESULTS: The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model | ||
| 520 | |a CONCLUSION: Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a antirheumatic agents | |
| 650 | 4 | |a communicable diseases | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a health care | |
| 650 | 4 | |a imported | |
| 650 | 4 | |a outcome assessment | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 700 | 1 | |a Leon, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Mucientes, Arkaitz |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Rodriguez, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Font Urgelles, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Madrid García, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Colomer, Jose I |e verfasserin |4 aut | |
| 700 | 1 | |a Jover, Juan A |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Gutierrez, Benjamín |e verfasserin |4 aut | |
| 700 | 1 | |a Abasolo, Lydia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 79(2020), 11 vom: 07. Nov., Seite 1393-1399 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2020 |g number:11 |g day:07 |g month:11 |g pages:1393-1399 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2020-217984 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2020 |e 11 |b 07 |c 11 |h 1393-1399 | ||